The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLIX.i

Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

Publications

Bautista MA, Stevens WT, Chen CS, Curtis BR, Aster RH, Hsueh CT

Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature.

Journal of hematology & oncology 2010 Mar 26;3;12 — 2010 Mar 26 — 12

Potenza S, Nasti G, Ottaiano A, Filippelli A, Rossi F, Capuano A

Severe respiratory symptoms to oxaliplatin infusion: a case report of delayed hypersensitivity reaction.

Investigational new drugs 2010 Apr;28;185-6 — 2010 Apr — 185-6

Elligers KT, Davies M, Sanchis D, Ferencz T, Saif MW

Rechallenge with cisplatin in a patient with pancreatic cancer who developed a hypersensitivity reaction to oxaliplatin. Is skin test useful in this setting?

JOP : Journal of the pancreas 2008 Mar 08;9;197-202 — 2008 Mar 08 — 197-202

Maindrault-Goebel F, André T, Tournigand C, Louvet C, Perez-Staub N, Zeghib N, De Gramont A

Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients.

European journal of cancer (Oxford, England : 1990) 2005 Oct;41;2262-7 — 2005 Oct — 2262-7

Lim KH, Huang MJ, Lin HC, Su YW, Chang YF, Lin J, Chang MC, Hsieh RK

Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule.

Anti-cancer drugs 2004 Jul;15;605-7 — 2004 Jul — 605-7

Brandi G, Pantaleo MA, Galli C, Falcone A, Antonuzzo A, Mordenti P, Di Marco MC, Biasco G

Hypersensitivity reactions related to oxaliplatin (OHP).

British journal of cancer 2003 Aug 04;89;477-81 — 2003 Aug 04 — 477-81